46.00
전일 마감가:
$45.43
열려 있는:
$45.39
하루 거래량:
657.58K
Relative Volume:
0.82
시가총액:
$2.58B
수익:
$651.97M
순이익/손실:
$59.71M
주가수익비율:
43.01
EPS:
1.0696
순현금흐름:
$172.03M
1주 성능:
+1.95%
1개월 성능:
+22.57%
6개월 성능:
+43.79%
1년 성능:
+33.80%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
명칭
Supernus Pharmaceuticals Inc
전화
301-838-2500
주소
9715 KEY WEST AVENUE, ROCKVILLE, MD
SUPN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SUPN
Supernus Pharmaceuticals Inc
|
46.00 | 2.55B | 651.97M | 59.71M | 172.03M | 1.0696 |
![]()
ZTS
Zoetis Inc
|
153.32 | 67.90B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.40 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.80 | 44.04B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.95 | 21.20B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
400.52 | 17.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2025-02-19 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
2024-09-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-01-03 | 재개 | Jefferies | Buy |
2021-12-01 | 재개 | Jefferies | Buy |
2021-04-13 | 업그레이드 | Jefferies | Hold → Buy |
2020-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2020-06-15 | 재개 | Jefferies | Hold |
2019-11-08 | 다운그레이드 | Berenberg | Buy → Hold |
2019-11-07 | 다운그레이드 | Stifel | Buy → Hold |
2019-11-06 | 다운그레이드 | Jefferies | Buy → Hold |
2018-11-12 | 재확인 | B. Riley FBR | Buy |
2018-01-18 | 재확인 | B. Riley FBR, Inc. | Buy |
2017-12-28 | 재확인 | B. Riley FBR, Inc. | Buy |
2017-12-04 | 업그레이드 | Janney | Neutral → Buy |
2017-11-08 | 업그레이드 | Stifel | Hold → Buy |
2017-10-19 | 개시 | FBR & Co. | Buy |
2017-09-19 | 다운그레이드 | Stifel | Buy → Hold |
2017-07-17 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2017-07-14 | 개시 | Janney | Neutral |
2017-06-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2016-07-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
2016-07-18 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2016-02-08 | 업그레이드 | Jefferies | Hold → Buy |
2015-11-05 | 재확인 | Northland Capital | Outperform |
2015-10-28 | 개시 | Northland Capital | Outperform |
모두보기
Supernus Pharmaceuticals Inc 주식(SUPN)의 최신 뉴스
Will Supernus Pharmaceuticals Inc. benefit from rising consumer demandPortfolio Return Summary & High Conviction Buy Zone Picks - خودرو بانک
Stock Analysis: Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesJuly 2025 Outlook & Daily Chart Pattern Signal Reports - خودرو بانک
How to use a screener to detect Supernus Pharmaceuticals Inc. breakouts2025 Sector Review & AI Based Buy/Sell Signal Reports - Newser
Is Supernus Pharmaceuticals Inc. benefiting from interest rate changesEarnings Recap Summary & Precise Buy Zone Tips - خودرو بانک
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Can Supernus Pharmaceuticals Inc. expand into new markets2025 Price Targets & Free Community Supported Trade Ideas - خودرو بانک
Analyzing recovery setups for Supernus Pharmaceuticals Inc. investorsMarket Trend Review & Daily Stock Momentum Reports - Newser
Will Supernus Pharmaceuticals Inc. benefit from sector rotationJuly 2025 Gainers & AI Driven Stock Movement Reports - خودرو بانک
Analyzing net buyer seller activity in Supernus Pharmaceuticals Inc.July 2025 Sentiment & Weekly Breakout Stock Alerts - Newser
What’s the beta of Supernus Pharmaceuticals Inc. stockMarket Trend Report & Weekly Return Optimization Alerts - خودرو بانک
Has Supernus Pharmaceuticals Inc. found a price floorWeekly Profit Summary & Daily Chart Pattern Signals - Newser
How high can Supernus Pharmaceuticals Inc. stock goJuly 2025 PreEarnings & Real-Time Price Movement Reports - Newser
Supernus at Wells Fargo Conference: Strategic Growth in CNS By Investing.com - Investing.com Canada
Will Supernus Pharmaceuticals Inc. benefit from geopolitical trends2025 Investor Takeaways & Low Risk Growth Stock Ideas - خودرو بانک
Published on: 2025-09-04 06:09:28 - Newser
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Predicting Supernus Pharmaceuticals Inc. trend using moving averagesMarket Risk Analysis & Long-Term Safe Investment Ideas - Newser
How sentiment analysis helps forecast Supernus Pharmaceuticals Inc.July 2025 Setups & High Yield Equity Trading Tips - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Will earnings trigger a reversal in Supernus Pharmaceuticals Inc.July 2025 Summary & Safe Capital Preservation Plans - Newser
Will Supernus Pharmaceuticals Inc. benefit from seasonalityMarket Sentiment Review & Reliable Entry Point Alerts - خودرو بانک
Real time breakdown of Supernus Pharmaceuticals Inc. stock performanceNew Guidance & Intraday High Probability Alerts - Newser
Risk vs reward if holding onto Supernus Pharmaceuticals Inc.July 2025 Pullbacks & High Conviction Buy Zone Alerts - Newser
Custom strategy builders for tracking Supernus Pharmaceuticals Inc.July 2025 Final Week & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Supernus Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Sector ETF performance correlation with Supernus Pharmaceuticals Inc.2025 Price Action Summary & AI Driven Price Predictions - Newser
Candlestick signals on Supernus Pharmaceuticals Inc. stock today2025 Technical Patterns & Real-Time Buy Signal Notifications - Newser
Will Supernus Pharmaceuticals Inc. stock recover after earnings2025 Market Overview & Low Risk Profit Maximizing Plans - خودرو بانک
Supernus Pharmaceuticals stock hits 52-week high at $45.85 - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at $45.85 By Investing.com - Investing.com UK
EV Market: What are Supernus Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Return Report & Detailed Earnings Play Strategies - خودرو بانک
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - Yahoo Finance
Using data filters to optimize entry into Supernus Pharmaceuticals Inc.Earnings Recap Report & Fast Entry Momentum Alerts - Newser
What hedge funds are buying Supernus Pharmaceuticals Inc.July 2025 Decliners & AI Driven Price Forecasts - خودرو بانک
Is Supernus Pharmaceuticals Inc. stock showing strong momentum2025 Biggest Moves & Daily Profit Maximizing Tips - خودرو بانک
What technical models suggest about Supernus Pharmaceuticals Inc.’s comebackPrice Action & Reliable Entry Point Trade Alerts - Newser
Market Outlook: What is the long term forecast for Supernus Pharmaceuticals Inc. stockBear Alert & Safe Entry Momentum Stock Tips - خودرو بانک
What are Supernus Pharmaceuticals Inc.’s earnings expectationsWeekly Risk Report & Stepwise Trade Execution Plans - خودرو بانک
Recovery Signals Appearing in Supernus Pharmaceuticals Inc. Charts getLinesFromResByArray error: size == 0 - 더경남뉴스
Supernus Pharmaceuticals Inc (SUPN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Supernus Pharmaceuticals Inc 주식 (SUPN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Khattar Jack A. | President, CEO |
Aug 28 '25 |
Option Exercise |
12.98 |
38,779 |
503,351 |
1,116,783 |
Khattar Jack A. | President, CEO |
Aug 27 '25 |
Option Exercise |
12.98 |
17,195 |
223,191 |
1,088,654 |
Khattar Jack A. | President, CEO |
Aug 28 '25 |
Sale |
45.12 |
24,150 |
1,089,648 |
1,092,633 |
Khattar Jack A. | President, CEO |
Aug 27 '25 |
Sale |
45.05 |
10,650 |
479,782 |
1,078,004 |
NEWHALL CHARLES W III | Director |
Aug 27 '25 |
Sale |
45.01 |
3,588 |
161,496 |
129,644 |
자본화:
|
볼륨(24시간):